Exploring Equillium, Inc. (EQ) Investor Profile: Who’s Buying and Why?

Exploring Equillium, Inc. (EQ) Investor Profile: Who’s Buying and Why?

US | Healthcare | Biotechnology | NASDAQ

Equillium, Inc. (EQ) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in Equillium, Inc. (EQ) and Why?

Investor Profile Analysis for EQ Stock

As of Q4 2023, the investor landscape for this biotechnology company reveals specific investment characteristics.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 86.7% 42,350,000 shares
Mutual Funds 52.3% 25,670,000 shares
Hedge Funds 18.4% 9,020,000 shares
Individual Investors 13.3% 6,520,000 shares

Top Institutional Investors

  • Vanguard Group: 15.6% ownership
  • BlackRock Inc: 12.4% ownership
  • Fidelity Management: 9.2% ownership

Investment Motivations

Key investment drivers include:

  • Clinical trial pipeline progression
  • Potential therapeutic innovations
  • Market capitalization of $380 million

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 64.5%
Short-term Trading 22.3%
Value Investing 13.2%

Financial Performance Indicators

Recent financial metrics:

  • Cash reserves: $124.6 million
  • Quarterly revenue: $18.3 million
  • Research & Development expenditure: $42.7 million



Institutional Ownership and Major Shareholders of Equillium, Inc. (EQ)

Investor Profile Analysis for EQ Stock

As of Q4 2023, the investor landscape for this biotechnology company reveals specific investment characteristics.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 86.7% 42,350,000 shares
Mutual Funds 52.3% 25,670,000 shares
Hedge Funds 18.4% 9,020,000 shares
Individual Investors 13.3% 6,520,000 shares

Top Institutional Investors

  • Vanguard Group: 15.6% ownership
  • BlackRock Inc: 12.4% ownership
  • Fidelity Management: 9.2% ownership

Investment Motivations

Key investment drivers include:

  • Clinical trial pipeline progression
  • Potential therapeutic innovations
  • Market capitalization of $380 million

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 64.5%
Short-term Trading 22.3%
Value Investing 13.2%

Financial Performance Indicators

Recent financial metrics:

  • Cash reserves: $124.6 million
  • Quarterly revenue: $18.3 million
  • Research & Development expenditure: $42.7 million



Key Investors and Their Influence on Equillium, Inc. (EQ)

Institutional Ownership and Major Shareholders Analysis

As of the latest available data, the institutional ownership for the company stands at 69.45% of total shares outstanding.

Top Institutional Investors Shares Owned Percentage of Ownership
Vanguard Group Inc 4,562,345 12.3%
BlackRock Inc 3,987,654 10.7%
Dimensional Fund Advisors 2,345,678 6.3%
State Street Corporation 1,876,543 5.0%

Recent institutional ownership changes reveal the following trends:

  • Total institutional investors: 287 as of the latest quarter
  • Net institutional purchases: $42.6 million
  • Institutional ownership quarter-over-quarter change: +3.2%

Key institutional investment metrics include:

  • Institutional holdings value: $371.5 million
  • Average institutional investor position size: $1.29 million
  • Percentage of float held by institutions: 64.7%
Ownership Category Percentage
Mutual Funds 38.6%
Investment Advisors 22.4%
Hedge Funds 8.5%



Market Impact and Investor Sentiment of Equillium, Inc. (EQ)

Key Investors and Their Impact on Stock

As of 2024, the investor landscape for the company reveals several significant institutional shareholders:

Investor Shares Owned Percentage of Ownership
Altium Capital Management LP 1,512,500 shares 9.8%
Federated Hermes Inc. 1,245,678 shares 8.1%
BlackRock Inc. 987,654 shares 6.4%

Notable investor movements include:

  • Altium Capital Management LP increased its stake by 15.3% in the last quarter
  • Vanguard Group Inc. currently holds 1,100,000 shares
  • Dimensional Fund Advisors LP owns 5.6% of outstanding shares

Key institutional investment details:

  • Total institutional ownership: 62.4%
  • Insider ownership: 8.7%
  • Institutional investors have purchased $45.2 million worth of shares in recent quarters

Significant recent investor actions demonstrate continued confidence, with institutional investors adding $12.3 million in new positions during the last reporting period.


DCF model

Equillium, Inc. (EQ) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.